KLK3 and Familial prostate cancer: Benefits of the PSA biomarker on reducing prostate cancer-related mortality estimated between the European Randomised Study of Screening for Prostate Cancer (ERSPC), and the US Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) trial varied, while both studies identified trial design shortcomings5–8.